AKTIEN ::ActiveTrader CFD ::SaxoTrader FOREX :: MetaTrader FUTURES ::Strategy Runner HANDELSSYSTEME


Das ist direktbroker.de
|
Konto/Depot & Handel
|
Produkte
|
News & Aktienkurse
|
Unser Service
|

International-News
23.11.2009 | 07:30

Viksmoen, - Phase III results with SBG for diabetic foot ulcer not positive

For further information, please contact: CEO Lars Viksmoen, tel: 47 40620870

(Oslo/Tromsø, 23 November 2009) Biotec Pharmacon has received the results from both its phase III studies with SBG for diabetic foot ulcer and regrets to inform that the results are not positive. The studies failed to show superiority of SBG vs. placebo in terms of ulcer healing, and the company will thus not proceed with the further activities planned for this indication. "The completion of these phase III studies was a major milestone for Biotec Pharmacon, and the results are a disappointing setback for everybody involved, internally as well as externally," says CEO Lars Viksmoen in Biotec P
harmacon. Overall, the results from both studies are very consistent. Both groups received the best available general wound care, and on top of that either SBG or placebo. The primary endpoint of the phase III diabetic ulcer program was the percentage of target ulcers healed after eight weeks, which was at a 30 percent level in both treatment groups. No harmful effects to patients were reported. From a study design point of view, selecting another primary endpoint would not have resulted in a different outcome. Furthermore, response rates were similar between different clinical centres and countries. Samples are being collected for analysis of biological activity to exclude that SBG was exposed to any unexpected harm. Blinded interim analyses for both studies had already provided advice not to increase the size of the patient populations. The company has stressed that this merely outlined the following possible study outcomes; (i) that the treatment response from the two patient groups were trending towards demonstrating a significant difference between the two treatment groups, in either direction, or, (ii) that the difference was so small that not even a large increase in the size of the patient population would be expected to yield a statistically significant difference. As described above, the latter turned out to be the case. "We have been very careful not to take a positive outcome for granted but are obviously very disappointed to see that results received in earlier clinical stages were not confirmed in phase III. This is unfortunate, although not unique in the pharmaceutical industry," says Viksmoen. "We proceed with our ongoing phase III study with SBG for oral mucositis, where the results are expected in the first quarter next year. The Board and management will carefully consider the options for the further development of the SBG portfolio", says Viksmoen. Although the oral mucositis study is a completely different study, it is still part of the company's ulcers and wound franchise, and Biotec Pharmacon's expectations for these results have been lowered due to the outcome of the diabetic foot ulcer studies. Biotec Pharmacon also has a clinical program with SBG in immunotherapy of cancer, where pre-clinical and early stage clinical data indicate a synergistic effect between SBG and monoclonal antibodies. The company has also done pre-clinical research with interesting results looking into other indications for SBG. Furthermore, Biotec Marine Biochemicals, a fully owned subsidiary of Biotec Pharmacon, has a profitable and fast growing business with cold adapted enzymes targeting the molecular biology market.

For further information, please contact: CEO Lars Viksmoen, tel: 47 40620870

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.





Artikel 1 - 10 von 3633

09.02.10 11:30 Uhr
Market - Sedo Sees Growing Demand for Premium Domains - Sedo, the leading online domain marketplace and monetization provider, today announced the results of its 2009 Market Study, which includes never before...
09.02.10 11:24 Uhr
Leibinger - AdCapital AG english - Details of the person subject to the disclosure requirement Last name: Leibinger First name:...
09.02.10 11:10 Uhr
Technologies - Net-O2 Announces Industry’s First Field-Test Version of MEF9 & MEF14 Carrier Ethernet Tests - Net-O2 Technologies (www.net-o2.com) today announced the industry first MEF9 and MEF 14 field testing conformance test solutions on XenaCompact Ethernet test...
09.02.10 11:07 Uhr
Markets - Research and Markets: Energy Policies of IEA Countries: Spain - Research and Markets (http://www.researchandmarkets.com/research/c7959c/energy_policies_of) has announced the addition of the "Energy Policies of IEA...
09.02.10 11:06 Uhr
Operating - Orion Group Financial Statement Release of 2009 - Orion's net sales in 2009 totalled EUR 771.5 million (EUR 710.7 million in 2008), up by 8.5% on the previous year. * Operating profit was EUR 207.0 (185.0)...
09.02.10 11:06 Uhr
Liikevoitto - Orion-konsernin tilinpäätöstiedote vuodelta 2009 - Orionin liikevaihto vuodelta 2009 oli 771,5 miljoonaa euroa (710,7 miljoonaa euroa vuonna 2008) ja se kasvoi 8,5 % edellisestä vuodesta. · Liikevoitto...
09.02.10 11:04 Uhr
Holdings, - French Payments & Telecom Company Afone Named VeriFone VIP - VeriFone Holdings, Inc (NYSE: PAY), today announced that the Afone Group (EURONEXT: AFO), the leading French payments and telecoms company, has joined the...
09.02.10 11:04 Uhr
Curriculum - Adaptive Curriculum Introduces New CEO - Adaptive Curriculum today announces the appointment of Jim Bowler as its first Chief Executive Officer Bowler is an experienced educational technology leader...
09.02.10 11:01 Uhr
MuscleFlex - Muscle Flex and its Partners, TLK Fusion & Wesley Morris Entertainment, Confirm Discussions Underway with a Number of Hollywood Celebrities for The Complete Packageâ„¢, Reality Television Show - Muscle Flex Inc (www.MuscleFlex.com) (Pink Sheets:MFLI) confirmed today, along with its partners TLK Fusion (www.TLKFusion.com) and Wesley Morris...
09.02.10 10:29 Uhr
Wednesday, - Webcast from Nasdaq OMX: SSAB's year-end results 2009 - Time of briefing: Wednesday, February 10 at 10.00 a.m....
Artikel 1 - 10 von 3633


09.02.10 | 11:45 Uhr
H�ufige Fragen Seite weiterempfehlen Seite drucken


Sofortkontakt
  • Telefon
  • Callback
  • E-Mail

Sofortkontakt zu unseren Mitarbeitern: Kein Call-Center, keine Warteschleifen, kompetente Profis beraten Sie sofort

030 5900 911 0

International: +49 (30) 5900 911 0

Wir rufen Sie gerne zurück!


Schicken Sie uns einfach eine E-Mail an:

oder nutzen Sie unserKontaktformular

Die Vorteile von direktbroker.de